Literature DB >> 2718191

Purification and characterization of a major phospholipase A2 from Russell's viper (Vipera russelli) venom.

S Kasturi1, T V Gowda.   

Abstract

A major phospholipase A2 (VRV PL-VIIIa) which constitutes 24% of the whole Vipera russelli venom was purified to homogeneity by CM-Sephadex C-25 column chromatography followed by gel filtration on Sephadex G-50. VRV PL-VIIIa is a basic protein with a molecular weight of 11,800 by SDS-PAGE. This enzyme contributes 45% of the total PLA2 activity of the venom, but it is least toxic compared to other purified basic PLA2 enzymes prepared from V. russelli venom. The LD50 value (i.p.) of VRV PL-VIIIa is 5.3 mg/kg body wt. It shows neurotoxic symptoms and damages vital organs such as lung, liver and kidney at LD50 doses. It induces myonecrosis when injected i.m. into the thigh muscle of mice and edema when injected into the foot pads.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2718191     DOI: 10.1016/0041-0101(89)90136-0

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  22 in total

1.  Purification and characterization of a potent hemolytic toxin with phospholipase A2 activity from the venom of Indian Russell's viper.

Authors:  Amit K Chakraborty; Robert H Hall; Asoke C Ghose
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

2.  Synthesis, characterization and bioactivity studies of novel 1,3,4-oxadiazole small molecule that targets basic phospholipase A2 from Vipera russelli.

Authors:  Vivek Hamse Kameshwar; Kumar J R; Babu S Priya; S Nanjunda Swamy
Journal:  Mol Cell Biochem       Date:  2016-12-07       Impact factor: 3.396

3.  Neurotoxicity in Sri Lankan Russell's Viper (Daboia russelii) Envenoming is Primarily due to U1-viperitoxin-Dr1a, a Pre-Synaptic Neurotoxin.

Authors:  Anjana Silva; Sanjaya Kuruppu; Iekhsan Othman; Robert J A Goode; Wayne C Hodgson; Geoffrey K Isbister
Journal:  Neurotox Res       Date:  2016-07-11       Impact factor: 3.911

4.  Antibodies to a phospholipase A2 from Vipera russelli selectively neutralize venom neurotoxicity.

Authors:  S Kasturi; L M Rudrammaji; T V Gowda
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

5.  Inhibition of secretory phospholipase A(2) enzyme by bilirubin: a new role as endogenous anti-inflammatory molecule.

Authors:  Noor Mohamed Jameel; Brigitte M Frey; Felix J Frey; T Veerabasappa Gowda; Bannikuppe S Vishwanath
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

6.  Chemical modification of ascorbic acid and evaluation of its lipophilic derivatives as inhibitors of secretory phospholipase A(2) with anti-inflammatory activity.

Authors:  Riyaz Mohamed; K K Dharmappa; Shaista Tarannum; N M Jameel; S A Kannum; H S Ashrafulla; Lokanath Rai; Cletus Jmd' Souza; M A Shekhar; Bannikuppe S Vishwanath
Journal:  Mol Cell Biochem       Date:  2010-08-22       Impact factor: 3.396

7.  An aromatic, but not a basic, residue is involved in the toxicity of group-II phospholipase A2 neurotoxins.

Authors:  J Pungercar; I Krizaj; N S Liang; F Gubensek
Journal:  Biochem J       Date:  1999-07-01       Impact factor: 3.857

8.  Effects of chlorpromazine on the enzymatic and toxic properties of the most basic phospholipase A2 from Vipera russelli snake venom.

Authors:  A S Babu; T V Gowda
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

9.  Genistein, a potent inhibitor of secretory phospholipase A2: a new insight in down regulation of inflammation.

Authors:  Kattepura K Dharmappa; Riyaz Mohamed; Holenarasipura V Shivaprasad; Bannikuppe Sannanaik Vishwanath
Journal:  Inflammopharmacology       Date:  2009-11-06       Impact factor: 4.473

10.  Purification of a phospholipase A(2) from Daboia russelii siamensis venom with anticancer effects.

Authors:  Suchitra Khunsap; Narumol Pakmanee; Orawan Khow; Lawan Chanhome; Visith Sitprija; Montamas Suntravat; Sara E Lucena; John C Perez; Elda E Sánchez
Journal:  J Venom Res       Date:  2011-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.